Skip to main content

Table 1 General features of included RCTs

From: Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview

Author

Study

Country

Year

Study design

N

Treatment arms

Primary end point

Marèchal R

EudraCT

Belgium

2011

Randomized phase II

57

(Exp arm): FOLFOX × 2 → CRT (5 FU) → Sx

(Control): CRT (5 FU) → Sx

pCR

Fernandez-Martos C

GCR-3

Spain

2015

Randomized phase II

108

(Exp arm): CAPOX × 4 → CRT (CAPOX) → Sx

(Control): CRT (CAPOX) → Sx → CAPOX

pCR

Bujko K

POLISH II

Poland

2016

Randomized phase III

515

(Exp arm): SCRT → FOLFOX × 2 → Sx

(Control): CRT (FOLFOX × 3) → Sx

R0 resection rate

Moore J

WAIT

Australia

2017

Randomized phase II

49

(Exp arm): CRT (5FU) → 5 FU × 3 → Sx

(Control): CRT (5FU) → Sx

pCR

Kim SY

KCSG CO 14-03

Korea

2018

Randomized phase II

108

(Exp arm): CRT (capecitabine) → CAPOX × 2 → Sx

(Control): CRT (capecitabine) → Sx

Downstaging rate

Deng Y

FOWARC

China

2019

Randomized phase III

495

(Exp arm): mFOLFOX6 + CRT (5FU) → Sx → 5FU × 7

(Exp arm): mFOLFOX6 × 4–6 → Sx → mFOLFOX6 × 6–8

(Control): CRT (5FU) → Sx → 5FU × 7

3-yr DFS

Bahadoer RR

RAPIDO

Netherlands

2020

Randomized phase III

912

(Exp arm): SCRT → CAPOX × 6/FOLFOX × 9 → Sx

(Control): CRT (capecitabine) → Sx → CAPOX × 6/FOLFOX4 × 12

DrTF

Conroy T

PRODIGE-23

France

2021

Randomized phase III

461

(Exp arm): FOLFIRINOX × 6 → CRT (capecitabine) → Sx → FOLFOX × 6

(Control): CRT (capecitabine) → Sx → FOLFOX × 12

3-yr DFS